

# Roger Stupp

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5020947/publications.pdf>

Version: 2024-02-01

103  
papers

43,893  
citations

61984

43  
h-index

49909

87  
g-index

110  
all docs

110  
docs citations

110  
times ranked

31667  
citing authors

#	ARTICLE	IF	CITATIONS
1	Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. <i>New England Journal of Medicine</i> , 2005, 352, 987-996.	27.0	17,395
2	<i>MGMT</i> Gene Silencing and Benefit from Temozolomide in Glioblastoma. <i>New England Journal of Medicine</i> , 2005, 352, 997-1003.	27.0	6,573
3	Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. <i>Lancet Oncology</i> , The, 2009, 10, 459-466.	10.7	6,451
4	Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 2306.	7.4	1,619
5	Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2012, 13, 916-926.	10.7	1,075
6	Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 2535.	7.4	982
7	European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. <i>Lancet Oncology</i> , The, 2017, 18, e315-e329.	10.7	816
8	Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated <i>MGMT</i> promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 1100-1108.	10.7	800
9	Rindopemimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1373-1385.	10.7	776
10	Promising Survival for Patients With Newly Diagnosed Glioblastoma Multiforme Treated With Concomitant Radiation Plus Temozolomide Followed by Adjuvant Temozolomide. <i>Journal of Clinical Oncology</i> , 2002, 20, 1375-1382.	1.6	703
11	cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV". <i>Acta Neuropathologica</i> , 2018, 136, 805-810.	7.7	599
12	Chemoradiotherapy in Malignant Glioma: Standard of Care and Future Directions. <i>Journal of Clinical Oncology</i> , 2007, 25, 4127-4136.	1.6	474
13	Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. <i>Lancet Oncology</i> , The, 2016, 17, 1521-1532.	10.7	396
14	Changing Paradigms" An Update on the Multidisciplinary Management of Malignant Glioma. <i>Oncologist</i> , 2006, 11, 165-180.	3.7	357
15	cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. <i>Acta Neuropathologica</i> , 2020, 139, 603-608.	7.7	344
16	Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial. <i>Lancet</i> , The, 2015, 386, 1049-1056.	13.7	316
17	Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. <i>Lancet</i> , The, 2017, 390, 1645-1653.	13.7	307
18	Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. <i>Acta Neuropathologica</i> , 2018, 136, 153-166.	7.7	298

#	ARTICLE	IF	CITATIONS
19	Corticosteroids compromise survival in glioblastoma. <i>Brain</i> , 2016, 139, 1458-1471.	7.6	271
20	MST4 Phosphorylation of ATG4B Regulates Autophagic Activity, Tumorigenicity, and Radioresistance in Glioblastoma. <i>Cancer Cell</i> , 2017, 32, 840-855.e8.	16.8	188
21	MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges. <i>Neuro-Oncology</i> , 2019, 21, 167-178.	1.2	173
22	Optimal role of temozolomide in the treatment of malignant gliomas. <i>Current Neurology and Neuroscience Reports</i> , 2005, 5, 198-206.	4.2	168
23	Small cell lung cancer: state of the art and future perspectives. <i>Lung Cancer</i> , 2004, 45, 105-117.	2.0	150
24	IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma. <i>Clinical Cancer Research</i> , 2018, 24, 2559-2573.	7.0	147
25	Infiltrating T Cells Increase IDO1 Expression in Glioblastoma and Contribute to Decreased Patient Survival. <i>Clinical Cancer Research</i> , 2017, 23, 6650-6660.	7.0	141
26	The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria. <i>Neuro-Oncology</i> , 2017, 19, 625-635.	1.2	137
27	Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma. <i>JAMA Oncology</i> , 2018, 4, 495.	7.1	135
28	Are Integrins Still Practicable Targets for Anti-Cancer Therapy?. <i>Cancers</i> , 2019, 11, 978.	3.7	128
29	The accuracy of predicting survival in individual patients with cancer. <i>Journal of Neurosurgery</i> , 2014, 120, 24-30.	1.6	113
30	Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG. <i>Neuro-Oncology</i> , 2017, 19, 1119-1126.	1.2	107
31	Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial. <i>Lancet Oncology</i> , 2009, 10, 785-793.	10.7	106
32	Phase II Study of Radiotherapy and Temozolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without <i>MGMT</i> Promoter Hypermethylation (EORTC 26082). <i>Clinical Cancer Research</i> , 2016, 22, 4797-4806.	7.0	105
33	CAR T-Cell Therapies in Glioblastoma: A First Look. <i>Clinical Cancer Research</i> , 2018, 24, 535-540.	7.0	103
34	Ultrasound-mediated Delivery of Paclitaxel for Glioma: A Comparative Study of Distribution, Toxicity, and Efficacy of Albumin-bound Versus Cremophor Formulations. <i>Clinical Cancer Research</i> , 2020, 26, 477-486.	7.0	98
35	<i>MGMT</i> Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials. <i>Clinical Cancer Research</i> , 2019, 25, 1809-1816.	7.0	94
36	Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial. <i>Lancet Oncology</i> , 2021, 22, 1103-1114.	10.7	91

#	ARTICLE	IF	CITATIONS
37	Chromosome 7 gain and DNA hypermethylation at the HOXA10 locus are associated with expression of a stem cell related HOX-signature in glioblastoma. <i>Genome Biology</i> , 2015, 16, 16.	8.8	82
38	Withholding temozolomide in glioblastoma patients with unmethylated <i>MGMT</i> promoter—still a dilemma?: Table 1.. <i>Neuro-Oncology</i> , 2015, 17, 1425-1427.	1.2	78
39	The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033. <i>Acta Neuropathologica</i> , 2018, 135, 601-615.	7.7	76
40	Anaplastic astrocytoma in adults. <i>Critical Reviews in Oncology/Hematology</i> , 2007, 63, 72-80.	4.4	67
41	Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement. <i>Clinical Cancer Research</i> , 2022, 28, 594-602.	7.0	67
42	PRMT6 methylation of <i>RCC1</i> regulates mitosis, tumorigenicity, and radiation response of glioblastoma stem cells. <i>Molecular Cell</i> , 2021, 81, 1276-1291.e9.	9.7	54
43	Prognostic factors for low-grade gliomas. <i>Seminars in Oncology</i> , 2003, 30, 23-28.	2.2	52
44	The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients. <i>Neuro-Oncology</i> , 2019, 21, 1498-1508.	1.2	49
45	Extensive brainstem infiltration, not mass effect, is a common feature of end-stage cerebral glioblastomas. <i>Neuro-Oncology</i> , 2020, 22, 470-479.	1.2	49
46	Use of metformin and outcome of patients with newly diagnosed glioblastoma: Pooled analysis. <i>International Journal of Cancer</i> , 2020, 146, 803-809.	5.1	42
47	Activation of 4-1BBL+ B cells with CD40 agonism and IFN $\gamma$ elicits potent immunity against glioblastoma. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	42
48	ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma. <i>Nature Cancer</i> , 2021, 2, 1372-1386.	13.2	39
49	Symptom clusters in newly diagnosed glioma patients: which symptom clusters are independently associated with functioning and global health status?. <i>Neuro-Oncology</i> , 2019, 21, 1447-1457.	1.2	35
50	Leptomeningeal metastasis from solid tumors. <i>Journal of the Neurological Sciences</i> , 2020, 411, 116706.	0.6	34
51	<i>De novo</i> purine biosynthesis is a major driver of chemoresistance in glioblastoma. <i>Brain</i> , 2021, 144, 1230-1246.	7.6	30
52	Temporal Muscle Thickness as a Prognostic Marker in Patients with Newly Diagnosed Glioblastoma: Translational Imaging Analysis of the CENTRIC EORTC 26071 and CORE Trials. <i>Clinical Cancer Research</i> , 2022, 28, 129-136.	7.0	25
53	Imaging tryptophan uptake with positron emission tomography in glioblastoma patients treated with indoximod. <i>Journal of Neuro-Oncology</i> , 2019, 141, 111-120.	2.9	24
54	Temporal activation of WNT/ $\beta$ -catenin signaling is sufficient to inhibit SOX10 expression and block melanoma growth. <i>Oncogene</i> , 2020, 39, 4132-4154.	5.9	23

#	ARTICLE	IF	CITATIONS
55	The added value of health-related quality of life as a prognostic indicator of overall survival and progression-free survival in glioma patients: a meta-analysis based on individual patient data from randomised controlled trials. <i>European Journal of Cancer</i> , 2019, 116, 190-198.	2.8	22
56	Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01). <i>Journal of Thoracic Oncology</i> , 2019, 14, 115-123.	1.1	21
57	Ribosomal protein S11 influences glioma response to TOP2 poisons. <i>Oncogene</i> , 2020, 39, 5068-5081.	5.9	21
58	Impact of Radiation Target Volume on Health-Related Quality of Life in Patients With Low-Grade Glioma in the 2-Year Period Post Treatment: A Secondary Analysis of the EORTC 22033-26033. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 90-100.	0.8	20
59	The Impact of Tumor Treating Fields on Glioblastoma Progression Patterns. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 1269-1278.	0.8	20
60	Methylome analyses of three glioblastoma cohorts reveal chemotherapy sensitivity markers within DDR genes. <i>Cancer Medicine</i> , 2020, 9, 8373-8385.	2.8	19
61	Overcoming the Blood-Brain Barrier with an Implantable Ultrasound Device. <i>Clinical Cancer Research</i> , 2019, 25, 3750-3752.	7.0	18
62	Tumor treating fields (TTFields): A novel treatment modality added to standard chemo- and radiotherapy in newly diagnosed glioblastoma—First report of the full dataset of the EF14 randomized phase III trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 2000-2000.	1.6	16
63	Establishing anchor-based minimally important differences for the EORTC QLQ-C30 in glioma patients. <i>Neuro-Oncology</i> , 2021, 23, 1327-1336.	1.2	15
64	Role of Resection in Glioblastoma Management. <i>Neurosurgery Clinics of North America</i> , 2021, 32, 9-22.	1.7	14
65	Prognostic significance of therapy-induced myelosuppression in newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2022, 24, 1533-1545.	1.2	13
66	Leptomeningeal metastases: the future is now. <i>Journal of Neuro-Oncology</i> , 2022, 156, 443-452.	2.9	11
67	<i>MGMT</i> promoter methylation is associated with patient age and 1p/19q status in IDH-mutant gliomas. <i>Neuro-Oncology</i> , 2021, 23, 858-860.	1.2	8
68	B cell-rich non-neoplastic sentinel lesion preceding primary central nervous system lymphoma. <i>Diagnostic Pathology</i> , 2018, 13, 37.	2.0	7
69	Radiotherapy in relation to temozolomide: Subgroup analysis of molecular markers of the randomized phase III study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033) in patients with a high risk low-grade glioma. <i>Journal of Clinical Oncology</i> , 2015, 33, 2006-2006.	1.6	7
70	Factors associated with health-related quality of life (HRQoL) deterioration in glioma patients during the progression-free survival period. <i>Neuro-Oncology</i> , 2022, 24, 2159-2169.	1.2	7
71	Neuro-oncology: oligodendroglioma and molecular markers. <i>Lancet Neurology</i> , The, 2007, 6, 10-12.	10.2	6
72	Evidence-based management of adult patients with diffuse glioma — Authors' reply. <i>Lancet Oncology</i> , The, 2017, 18, e430-e431.	10.7	5

#	ARTICLE	IF	CITATIONS
73	Go, no-go decision making for phase 3 clinical trials: ACT IV revisited – Authors' reply. <i>Lancet Oncology</i> , The, 2017, 18, e709-e710.	10.7	5
74	Measuring change in health-related quality of life: the impact of different analytical methods on the interpretation of treatment effects in glioma patients. <i>Neuro-Oncology Practice</i> , 2020, 7, 668-675.	1.6	5
75	Ultrasound-mediated Blood-brain barrier opening increases cell-free DNA in a time dependent manner. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab165.	0.7	5
76	PET Imaging in Glioma. <i>PET Clinics</i> , 2013, 8, 117-128.	3.0	4
77	Translocon-associated Protein Subunit SSR3 Determines and Predicts Susceptibility to Paclitaxel in Breast Cancer and Glioblastoma. <i>Clinical Cancer Research</i> , 2022, 28, 3156-3169.	7.0	4
78	CTIM-12. A PHASE 1 TRIAL OF IMMUNORADIOTHERAPY WITH THE IDO ENZYME INHIBITOR (BMS-986205) AND NIVOLUMAB IN PATIENTS WITH NEWLY DIAGNOSED MGMT PROMOTER UNMETHYLATED IDHwt GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2021, 23, vi51-vi52.	1.2	3
79	Radiotherapy with Concurrent and Adjuvant Temozolomide: A New Standard of Care for Glioblastoma Multiforme. <i>Progress in Neurotherapeutics and Neuropsychopharmacology</i> , 2006, 1, 37-52.	0.0	2
80	Radiotherapy with concurrent and adjuvant temozolomide: a new standard of care for glioblastoma multiforme. , 0, , 37-52.		1
81	QOLP-11. QUALITY OF LIFE IN HIGH-GRADE GLIOMA PATIENTS ON A PHASE I VIROTHERAPY STUDY. <i>Neuro-Oncology</i> , 2018, 20, vi216-vi216.	1.2	1
82	ACTR-40. A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF MARIZOMIB (MRZ) WITH TEMOZOLOMIDE (TMZ) AND RADIOTHERAPY (RT) IN NEWLY DIAGNOSED WHO GRADE IV MALIGNANT GLIOMA (GLIOBLASTOMA), Tj ETQq0.0 0 rgBTi/Overlock		
83	QOLP-03. MEASURING CHANGE IN HEALTH-RELATED QUALITY OF LIFE: THE ADDED VALUE OF ANALYSIS ON THE INDIVIDUAL PATIENT LEVEL IN GLIOMA PATIENTS IN CLINICAL DECISION MAKING. <i>Neuro-Oncology</i> , 2019, 21, vi197-vi198.	1.2	1
84	Calculating the net clinical benefit in neuro-oncology clinical trials using two methods: quality-adjusted survival effect sizes and joint modeling. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa147.	0.7	1
85	CTNI-47. INTERIM RESULTS OF NCT03011671: A MULTI-INSTITUTIONAL PHASE I STUDY OF ACETAZOLAMIDE WITH TEMOZOLOMIDE IN ADULTS WITH NEWLY DIAGNOSED MGMT-METHYLATED MALIGNANT GLIOMA. <i>Neuro-Oncology</i> , 2021, 23, vi70-vi70.	1.2	1
86	EXTH-29. DUAL TGFB AND PD1 BLOCKADE PROMOTES GERMINAL-CENTER B-CELL IMMUNE RESPONSES AGAINST GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2021, 23, vi169-vi169.	1.2	1
87	CTNI-31. INTERIM RESULTS OF A PHASE I/IIA STUDY TO EVALUATE THE SAFETY AND EFFICACY OF BBB OPENING WITH THE SONOCLOUD-9 IMPLANTABLE ULTRASOUND DEVICE IN RECURRENT GLIOBLASTOMA PATIENTS PRIOR TO IV CARBOPLATIN. <i>Neuro-Oncology</i> , 2020, 22, ii49-ii49.	1.2	1
88	Associations of levetiracetam use with the safety and tolerability profile of chemoradiotherapy for patients with newly diagnosed glioblastoma. <i>Neuro-Oncology Advances</i> , 2022, 4, .	0.7	1
89	IMMU-22. COMBINATION IMMUNOTHERAPY WITH IDO1 INHIBITION ENHANCES TREATMENT EFFICACY IN MULTIPLE MODELS OF GLIOBLASTOMA MODEL. <i>Neuro-Oncology</i> , 2017, 19, vi117-vi117.	1.2	0
90	QOLP-29. SYMPTOM CLUSTERS IN NEWLY DIAGNOSED GLIOMA PATIENTS: WHICH CLUSTERS ARE ASSOCIATED WITH FUNCTIONING AND GLOBAL HEALTH STATUS?. <i>Neuro-Oncology</i> , 2018, 20, vi221-vi221.	1.2	0

#	ARTICLE	IF	CITATIONS
91	CSIG-18. MODELING TEMOZOLOMIDE RESISTANCE WITH GLIOBLASTOMA PATIENT DERIVED XENOGRAFTS. <i>Neuro-Oncology</i> , 2018, 20, vi46-vi47.	1.2	0
92	CSIG-35. MST4 PHOSPHORYLATION OF ATG4B REGULATES AUTOPHAGIC ACTIVITY, TUMORIGENICITY, AND RADIORESISTANCE IN GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, vi50-vi51.	1.2	0
93	ACTR-57. A PHASE 1/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF BLOOD-BRAIN BARRIER (BBB) OPENING WITH A NINE-EMITTER IMPLANTABLE ULTRASOUND DEVICE IN RECURRENT GLIOBLASTOMA PATIENTS PRIOR TO CARBOPLATIN. <i>Neuro-Oncology</i> , 2019, 21, vi26-vi27.	1.2	0
94	CMET-11. RESPONSE TO STEREOTACTIC RADIOSURGERY FOR MULTIPLE BRAIN METASTASES BASED ON HISTOLOGY-SPECIFIC SUBTYPE STATUS. <i>Neuro-Oncology</i> , 2019, 21, vi53-vi53.	1.2	0
95	QOLP-04. CALCULATING THE NET CLINICAL BENEFIT IN BRAIN TUMOR TRIALS BY COMBINING SURVIVAL AND HEALTH-RELATED QUALITY OF LIFE DATA USING TWO METHODS: QUALITY ADJUSTED SURVIVAL EFFECT SIZES AND JOINT MODELLING. <i>Neuro-Oncology</i> , 2019, 21, vi198-vi198.	1.2	0
96	Experiences and views of different key stakeholders on the feasibility of treating cancer-related fatigue. <i>BMC Cancer</i> , 2020, 20, 458.	2.6	0
97	Tumor type, epilepsy burden, and seizure documentation: experiences at a single center neuro-oncology clinic. <i>Neuro-Oncology Practice</i> , 2021, 8, 581-588.	1.6	0
98	EXTH-36. ELECTROCONVULSIVE SEIZURE-INDUCED CHANGES IN THE TUMOR MICROENVIRONMENT PROMOTE SURVIVAL IN GLIOMA-BEARING MICE. <i>Neuro-Oncology</i> , 2021, 23, vi171-vi171.	1.2	0
99	BIOM-31. ERK1/2 PHOSPHORYLATION PREDICTS SURVIVAL FOLLOWING ANTI-PD-1 IMMUNOTHERAPY IN RECURRENT GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2021, 23, vi17-vi17.	1.2	0
100	INNV-13. UNDERSTANDING FACTORS THAT INFLUENCE THE DECISION OF ACCEPTING TUMOR TREATING FIELDS (TTF) THERAPY. <i>Neuro-Oncology</i> , 2021, 23, vi107-vi108.	1.2	0
101	IMMU-29. B-CELL-BASED VACCINE PRODUCES GLIOBLASTOMA-REACTIVE ANTIBODIES THAT CONTRIBUTE TO TUMOR CLEARANCE. <i>Neuro-Oncology</i> , 2021, 23, vi98-vi98.	1.2	0
102	BIOM-32. ENDOPLASMIC RETICULUM PROTEIN SSR3 DETERMINES AND PREDICTS RESPONSE TO PACLITAXEL IN BREAST CANCER AND GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2021, 23, vi17-vi18.	1.2	0
103	TMOD-08. DEVELOPING DERIVATIVE GBM PDX, IN VIVO, FROM TREATMENT NAÏVE SOURCES. <i>Neuro-Oncology</i> , 2021, 23, vi217-vi217.	1.2	0